NCT06729229

Brief Summary

Cardiovascular disease (CVD) is one of the major causes of mortality, however, it is estimated that approximately 75% of all cases are preventable. Previous evidence has shown higher blood concentrations of n-3 polyunsaturated fatty acids (PUFAs) are associated with a lower risk of cardiovascular disease owing to their ability to lower inflammation. The omega-3 index (O3I) is a commonly used marker of n-3 PUFA status, which refers to the percentage of n-3 long chain PUFAs (with respect to total fatty acids) in red blood cell membranes, with an O3I of \>8% associated with the lowest risk of CVD. Concerningly it's estimated that most of the population have an O3I ranging from 4-5%. Fish is a rich source of polyunsaturated fatty acids (PUFA) and has been shown to be one of the main predictors of a higher O3I. Current guidelines recommend the consumption of 2 portions of fish per week; however, current UK and Irish intakes are well below the current recommendations, particularly amongst young people. Additionally, professional bodies have noted that a daily omega-3 supplement, providing approximately 500mg EPA + DHA per day, is beneficial in increasing omeag-3 intakes amongst those who may exclude dietary sources such as fish. The regular consumption of fish or omega 3 supplement use could help to increase the O3I, however, it remains unknown as to whether the guidance surrounding these methods are effective in reaching the recommended target of 8%. Early interventions such as increasing the O3I (throughfish and/or supplements) into a lower risk category may be an effective intervention in the prevention of CVD. This human intervention study will investigate the effects of omega 3 supplements and fish on the O3I and vascular health of young adults. It is hypothesised that increasing fish consumption or taking omega 3 supplements will increase the O3I and improve the vascular health of young adults.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 15, 2024

Completed
16 days until next milestone

Study Start

First participant enrolled

December 1, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 11, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2025

Completed
Last Updated

December 11, 2024

Status Verified

October 1, 2024

Enrollment Period

7 months

First QC Date

November 15, 2024

Last Update Submit

December 6, 2024

Conditions

Keywords

Polyunsaturated fatty acidsOmega 3 indexfish, fish consumptioncardiovascular disease.

Outcome Measures

Primary Outcomes (1)

  • Omega 3 index measured as percentage

    Assessed via Gas-Chromatography mass spectrometry

    Change at 8 weeks from baseline

Secondary Outcomes (1)

  • Polyunsaturated fatty acid status

    Time frame: change at 8 weeks from baseline

Other Outcomes (3)

  • Inflammatory status

    Change at 8 weeks from baseline

  • Lipid Profile

    Change at 8 weeks from baseline

  • Microbiota

    Change at 8 wees from baseline

Study Arms (4)

Fish and Placebo

EXPERIMENTAL

Participants will receive 2 portions of fish (280g)

Dietary Supplement: Placebo

No fish SUPPLEMENT

EXPERIMENTAL

Daily 1g omega-3 supplement

Dietary Supplement: Dietary Supplement/Vitamins

No fish PLACEBO

EXPERIMENTAL

Placebo

Dietary Supplement: Placebo

2 fish portion

EXPERIMENTAL

Omega 3 supplement

Dietary Supplement: Dietary Supplement/Vitamins

Interventions

PlaceboDIETARY_SUPPLEMENT

Experimental - 2 portions of fish (280g) per week and placebo supplement (corn oil)

Fish and Placebo
Dietary Supplement/VitaminsDIETARY_SUPPLEMENT

Experimental - Control lunch (no fish) and omega 3 supplement

2 fish portion

Eligibility Criteria

Age18 Years - 30 Years
Sexall(Gender-based eligibility)
Gender Eligibility DetailsBiological males and females will be recruited
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Omega 3 index \<6% Healthy males or females.
  • Aged 18-30 years old.
  • Low consumers of fish (\<2 portions/month).
  • Willing to 2 portions (280 grams) of fish per week.
  • Not consuming fish oil supplements.
  • Not consuming protein supplements.
  • Within a BMI of 18-30kg/m2
  • Not allergic to seafood

You may not qualify if:

  • Omega 3 index \>6%
  • Regularly consume fish.
  • Are allergic to seafood.
  • Are taking fish oil supplements (for example fish oil, cod oil, krill oil, GLA or evening primrose) or are taking protein supplements (for example whey protein).
  • Are pregnant/lactating.
  • Have existing health conditions such as Diabetes Mellitus and known hypertension.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NICHE, School of Biomedical Sciences, Biomedical Sciences Research, Coleraine Campus, University of Ulster

Coleraine, Co Londonderry, BT52 1SA, United Kingdom

Location

Related Publications (1)

  • McMullan JE, Kumar RA, Yeates AJ, Allsopp PJ, Mulhern MS, van Wijngaarden E, Strain JJ, McSorley EM. Influence of Fish Consumption and omega-3 Supplementation on the omega-3 Index of Young Adults: A 2 x 2 Factorial Randomized Controlled Trial (YouFish Study). J Nutr. 2025 Dec;155(12):4345-4355. doi: 10.1016/j.tjnut.2025.10.010. Epub 2025 Oct 11.

MeSH Terms

Conditions

Cardiovascular Diseases

Interventions

Dietary SupplementsVitamins

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesMicronutrientsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesNutrients

Study Officials

  • Emeir McSorley, PhD

    Ulster University, Cromore Road, Coleraine, Co. Londonderry, BT521SA.

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Emeir McSorley, PhD

CONTACT

Alison J Yeates, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 15, 2024

First Posted

December 11, 2024

Study Start

December 1, 2024

Primary Completion

June 30, 2025

Study Completion

July 31, 2025

Last Updated

December 11, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations